Xiaoyu Yang, a graduate student at Rice, is the lead author on a study published in the journal Science on smart cell design. Photo by Jeff Fitlow/ Courtesy Rice University

Bioengineers at Rice University have developed a “new construction kit” for building custom sense-and-respond circuits in human cells, representing a major breakthrough in the field of synthetic biology, which could "revolutionize" autoimmune disease and cancer therapeutics.

In a study published in the journal Science, the team focused on phosphorylation, a cellular process in the body in which a phosphate group is added to a protein, signaling a response. In multicellular organisms, phosphorylation-based signaling can involve a multistage, or a cascading-like effect. Rice’s team set out to show that each cycle in a cascade can be treated as an elementary unit, meaning that they can be reassembled in new configurations to form entirely novel pathways linking cellular inputs and outputs.

Previous research on using phosphorylation-based signaling for therapeutic purposes has focused on re-engineering pathways.

“This opens up the signaling circuit design space dramatically,” Caleb Bashor, assistant professor of bioengineering and biosciences and corresponding author on the study, said in a news release. “It turns out, phosphorylation cycles are not just interconnected but interconnectable … Our design strategy enabled us to engineer synthetic phosphorylation circuits that are not only highly tunable but that can also function in parallel with cells’ own processes without impacting their viability or growth rate.”

Bashor is the deputy director for the Rice Synthetic Biology Institute, which launched last year.

The Rice lab's sense-and-respond cellular circuit design is also innovative because phosphorylation occurs rapidly. Thus, the new circuits could potentially be programmed to respond to physiological events in minutes, compared to other methods, which take hours to activate.

Rice’s team successfully tested the circuits for sensitivity and their ability to respond to external signals, such as inflammatory issues. The researchers then used the framework to engineer a cellular circuit that can detect certain factors, control autoimmune flare-ups and reduce immunotherapy-associated toxicity.

“This work brings us a whole lot closer to being able to build ‘smart cells’ that can detect signs of disease and immediately release customizable treatments in response,” Xiaoyu Yang, a graduate student in the Systems, Synthetic and Physical Biology Ph.D. program at Rice who is the lead author on the study, said in a news release.

Ajo-Franklin, a professor of biosciences, bioengineering, chemical and biomolecular engineering and a Cancer Prevention and Research Institute of Texas Scholar, added “the Bashor lab’s work vaults us forward to a new frontier — controlling mammalian cells’ immediate response to change.”

These three entrepreneurs saw a need in their industries and created their own solutions. Photos courtesy

3 Houston innovators to know this week

Who's who

A true innovator is someone who's able to look past how something has been done for years — decades even — and be creative enough to find a better way to do it.

From redesigning conventional lab space to seeing a niche opportunity for luxury home rentals, these three innovators to know this week have made strides in changing the game.

Caleb Bashor, professor at Rice University

Photo courtesy of Caleb Bashor

Not all labs are created equal — or affordably. Caleb Bashor, a professor at Rice University, along with seven colleagues, created a DIY lab to further research efforts based at the university.

The DIY lab, eVOLVER, comprises three modules: a customizable "smart sleeve" housing and interface for each culture vessel, a fluidic module that controls movement of liquid in and out of each culture vessel, and a modular hardware infrastructure that simplifies high-volume bi-directional data flow by decoupling each parameter into individual microcontrollers.

"The prototype 16-chamber version of eVOLVER described in the new paper cost less than $2,000, cheaper than what a lab might pay for a single continuous culture bioreactor," Bashor says. Read more about the eVOLVER here.

Sébastien Long, founder and CEO of Lodgeur

Photo courtesy of Lodgeur

Sébastien Long ended up in Houston by chance, and the city ended up being a great place to take his luxe apartment rental business plan and turn it into a reality. Houston-based Lodgeur is a rental company that takes the convenience of Airbnb and adds in the luxury experience of a hotel.

Long identified stylish apartment complexes and built his business which now has a couple properties downtown that are attractive to a niche market of clientele.

"We're roughly split between leisure guests and business travelers," Long says. "They want to feel like they're staying in a home away from home." Read more about Lodgeur here.

Gustavo Sanchez, co-founder and CEO of Pandata Tech

Photo courtesy of Pandata Tech

In oil and gas, proper data management can be the difference of millions of dollars in savings. Pandata Tech can run a data quality check for its oil and gas clients — and even engages automation and machine learning for quicker, more thorough results.

Gustavo Sanchez, co-founder and CEO of the company, is looking to bring his data systems into new industries, like health care, where data management can be hectic, overwhelming, and crucial to life-saving opportunities.

"There's so much data, and it's so noisy, that it's hard to know whether the data can be trusted or not," Sanchez says. Read more about Pandata Tech here.

The DIY lab, called the eVOLVER, costs $2,000 less than a comparable setup. Photo courtesy of Rice University

Houston scientist creates a DIY lab concept for flexible and efficient work

Work space

Every scientist needs his or her own space, and each discipline calls for different types of tools and space requirements. Caleb Bashor, a professor at Rice University, along with seven colleagues, created a DIY lab to further research efforts based at the university.

Stemming from the need of a more customized study, Bashor and his team created a setup that combines the control of automated cell-culturing systems that can run continuously for months with the scale of high-throughput systems that grow dozens of cultures at once, according to a news release issued by Rice University.

The DIY lab, eVOLVER, comprises three modules: a customizable "smart sleeve" housing and interface for each culture vessel, a fluidic module that controls movement of liquid in and out of each culture vessel, and a modular hardware infrastructure that simplifies high-volume bi-directional data flow by decoupling each parameter into individual microcontrollers.

"The prototype 16-chamber version of eVOLVER described in the new paper cost less than $2,000, cheaper than what a lab might pay for a single continuous culture bioreactor," Bashor says in the release.

Bashor, who has been at the university since 2017, has worked in science for 15 years and received his post doctorate from Massachusetts Institute of Technology, where he met many of his colleagues that collaborated on eVOLVER.

"If you don't have something to do the job in the lab, you go and you build it," says Bashor. "It might take a few rounds of building and rebuilding, but eventually you get around to having it be something that gives you what you want. In this case, it's something a lot of different academic labs want now, we have actually given this out to dozens of labs."

The DIY initiative has made waves throughout the Rice student body, Bashor shares with InnovationMap. One graduate student, Brandon Wong, tasked to help with the project has shared a how-to for the DIY lab online.

"It's a basic research tool, it's exciting," says Bashor. It's something that can be leveraged for a lot of great research projects inside of the university."

Bashor and his team in the bioengineering department support lead cellular and biomolecular engineering research, which led them to create the lab.

"We turned to DIY electronics and we decided to build it ourselves," Bashor tells InnovationMap. "The process took about three years. We had to learn all of the tools that were out there for doing DIY work and a lot of these tools have showed up in the last ten years."

Rice University's department of bioengineering is a member of the Texas Medical Center and hosts interdisciplinary training programs at MD Anderson Cancer Center and Baylor College of Medicine, according to the school's website.

"This is one of the biggest centers in the world for immunotherapy, particularly clinical immunotherapy, and so we're working with people who do immunotherapy using my special engineering techniques, which mostly involve engineering the way that cells behave to try to more effectively kill cancer," says Bashor.

Caleb Bashor and his associates created the lab. Photo courtesy of Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.